BRAF and melanoma: To uncover how drug endurance levels drive metabolic shifts, we performed an integrative analysis of metabolome and transcriptome data from isogenic human metastatic BRAFV600E melanoma models with variant vemurafenib tolerance thresholds (M14 VemR and A2058 VemR with IC50 100 nM and 5 μM, respectively) and patient-derived brain metastatic melanomas with wild-type (Mel 14-089) or V600E mutant (Mel 14-108) BRAF.